Post-earnings recap
Reported
Thu, Feb 27, 2014
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Sarepta Therapeutics reported a loss per share that was slightly worse than expected, but the stock still rose by 1.39%. This increase may reflect investor optimism about the company's ongoing clinical trials, despite the lack of revenue information and forward guidance. The market seems to be focusing on long-term potential rather than short-term earnings performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.77 | N/A | -9.69% |
| Revenue | N/A | N/A | N/A |
Management expressed caution regarding future performance without providing specific guidance. They emphasized their commitment to advancing clinical programs.
Management did not provide specific guidance for the upcoming quarters.
The company remains focused on its ongoing clinical trials.